학술논문
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Document Type
Article
Author
Source
In: Diabetologia . (Diabetologia, March 2024, 67(3):470-482)
Subject
Language
English
ISSN
14320428
0012186X
0012186X